 |
|
|
|
 |
 |
Investigator |
|
Institution |
|
Project |
|
|
Terri S. Armstrong, DSN, APRN, BC* |
|
M.D. Anderson Cancer Center |
|
Gauging Impact of Treatment on Symptoms, Health Related Quality of Life and Neurocognitive Function in Patients with Primary Brain Tumors |
|
|
Martin Brown, PhD |
|
Stanford University |
|
Sensitization of brain tumors to radiotherapy |
|
|
Santosh Kesari, MD, PhD |
|
Dana-Farber Cancer Institute |
|
Notch inhibition in malignant gliomas |
|
|
Ingo Mellinghoff, MD |
|
University of California Los Angeles |
|
Developing biomarkers for oncogenic EGFR signaling in glioblastoma |
|
|
Keith Rich, MD |
|
Washington University |
|
Transglutaminase 2 inhibitor, KCC009, sensitizes glioblastomas to chemotherapy |
|
|
John Sampson, MD, PhD |
|
Duke University |
|
Inactivation of regulatory T-cells to enhance immunotherapy against cytomegalovirus antigens in glioblastoma multiforme |
|
|
Qing-Bai She, PhD |
|
Memorial Sloan-Kettering Cancer Center |
|
Development of therapeutic strategies for the inhibition of PI3K/Akt kinase-mediated signaling pathways in glioblastoma |
|
|
Al Yung, MD |
|
MD Anderson Cancer Center |
|
Evaluation of small molecule inhibitors of the PI3K/Akt pathway |
|
| |
 |
|
|
|
 |
